GZMB and cancer: Additionally, as already mentioned, both GzmB from killer cytotoxic lymphocytes18 or combined BRAF inhibitor and MEK inhibitor treatment39 can trigger GSDME‐dependent pyroptosis in cancer cells downstream of caspase‐3 activation (Figure 2b).